CN116615250A - 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗 - Google Patents

通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗 Download PDF

Info

Publication number
CN116615250A
CN116615250A CN202180076478.0A CN202180076478A CN116615250A CN 116615250 A CN116615250 A CN 116615250A CN 202180076478 A CN202180076478 A CN 202180076478A CN 116615250 A CN116615250 A CN 116615250A
Authority
CN
China
Prior art keywords
amino acid
seq
acid residues
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076478.0A
Other languages
English (en)
Chinese (zh)
Inventor
大和美智子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN116615250A publication Critical patent/CN116615250A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202180076478.0A 2020-11-12 2021-11-11 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗 Pending CN116615250A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-188910 2020-11-12
JP2020188910 2020-11-12
PCT/JP2021/041496 WO2022102695A1 (ja) 2020-11-12 2021-11-11 抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療

Publications (1)

Publication Number Publication Date
CN116615250A true CN116615250A (zh) 2023-08-18

Family

ID=81601304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076478.0A Pending CN116615250A (zh) 2020-11-12 2021-11-11 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗

Country Status (8)

Country Link
US (1) US20230398230A1 (https=)
EP (1) EP4245322A4 (https=)
JP (1) JPWO2022102695A1 (https=)
KR (1) KR20230107239A (https=)
CN (1) CN116615250A (https=)
CA (1) CA3198382A1 (https=)
TW (1) TW202233249A (https=)
WO (1) WO2022102695A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103377A1 (zh) * 2023-11-13 2025-05-22 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法
WO2025131054A1 (en) * 2023-12-22 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025256632A1 (zh) * 2024-06-14 2025-12-18 长春金赛药业有限责任公司 靶向b7-h3和psma的双特异性抗体及抗体-药物偶联物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
EP4642490A1 (en) * 2022-12-29 2025-11-05 Beone Medicines I GmbH B7h3 antibody drug conjugates
JP2026508145A (ja) 2023-02-09 2026-03-10 ビーワン メディシンズ ワン ゲーエムベーハー 自己安定化リンカーコンジュゲート
CN120957753A (zh) 2023-03-23 2025-11-14 广州百济神州生物制药有限公司 生物活性结合物、其制备方法和其用途
EP4696332A1 (en) * 2023-04-10 2026-02-18 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate with atr inhibitor or atm inhibitor
TW202500198A (zh) 2023-06-29 2025-01-01 瑞士商百濟神州瑞士有限責任公司 生物活性偶聯物、其製備方法及用途
CN121568721A (zh) 2023-06-29 2026-02-24 广州百济神州生物制药有限公司 生物活性缀合物、其制备方法和其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922477A (zh) * 2015-06-29 2018-04-17 第三共株式会社 用于选择性制造抗体‑药物缀合物的方法
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
CN110944667A (zh) * 2017-08-23 2020-03-31 第一三共株式会社 抗体-药物缀合物制剂及其冻干

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
KR100973622B1 (ko) 2005-07-29 2010-08-02 학교법인 도시샤 섬유 강화 열가소성 복합 재료의 성형 방법 및 그 중간체,그리고 복합 시트
CA2862925C (en) 2012-02-10 2020-01-21 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
LT3424955T (lt) 2013-12-25 2025-06-25 Daiichi Sankyo Company, Limited Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
SI3466976T1 (sl) 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
KR102399277B1 (ko) 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
WO2017141604A1 (ja) * 2016-02-15 2017-08-24 地方独立行政法人神奈川県立病院機構 膜型ムチン様タンパク質の認識とその医療応用
ES3057444T3 (en) 2017-08-31 2026-03-02 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922477A (zh) * 2015-06-29 2018-04-17 第三共株式会社 用于选择性制造抗体‑药物缀合物的方法
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
CN110944667A (zh) * 2017-08-23 2020-03-31 第一三共株式会社 抗体-药物缀合物制剂及其冻干

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS: "Safety Study of MGD009 in B7-H3-expressing Tumors", Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT02628535?term=MGD009&rank=1&tab=history&a=16#version-content-panel> *
LUANA CALABRÒ等: "Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications", 《JOURNAL OF CELLULAR PHYSIOLOGY》, vol. 226, no. 10, 31 October 2011 (2011-10-31), pages 2595 - 2600 *
STEVEN G GRAY等: "Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives", 《TRANSLATIONAL LUNG CANCER RESEARCH》, vol. 9, no. 1, 29 February 2020 (2020-02-29), pages 108 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103377A1 (zh) * 2023-11-13 2025-05-22 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法
WO2025131054A1 (en) * 2023-12-22 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025256632A1 (zh) * 2024-06-14 2025-12-18 长春金赛药业有限责任公司 靶向b7-h3和psma的双特异性抗体及抗体-药物偶联物

Also Published As

Publication number Publication date
EP4245322A1 (en) 2023-09-20
KR20230107239A (ko) 2023-07-14
EP4245322A4 (en) 2025-09-10
JPWO2022102695A1 (https=) 2022-05-19
WO2022102695A1 (ja) 2022-05-19
US20230398230A1 (en) 2023-12-14
CA3198382A1 (en) 2022-05-19
TW202233249A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
CN116615250A (zh) 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗
JP7204651B2 (ja) 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
CN113271942A (zh) 抗体-药物缀合物与parp抑制剂的组合
JP7769032B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
JP2024109885A (ja) 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
CN112512587A (zh) 抗体药物缀合物和微管蛋白抑制剂的组合
CN120501882A (zh) 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
HK40091702A (en) Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate
CN115884794A (zh) 抗her2抗体药物缀合物与her二聚化抑制剂的组合
RU2789476C2 (ru) Получение конъюгата антитело-лекарственное средство и его лиофилизация
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
EA046932B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
EP4696328A1 (en) Therapeutic method for low-drug-sensitivity cancers by administration of anti-muc1 antibody-drug conjugate
HK40130006A (zh) 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
HK40086585A (en) Combination of (anti-her2 antibody)-drug conjugate and her dimerization inhibitor
EA051330B1 (ru) Комбинация конюгата антитело против her2-лекарственное средство с ингибитором димеризации her
HK40045208A (en) Treatment of metastatic brain tumor by administration of antibody-drug conjugate
EA045144B1 (ru) Лечение her2-мутированного рака введением конъюгата анти-her2-антитело-лекарственное средство
EA053135B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination